{"schema_version":"secwatch.filing_event.v1","accession":"0001285550-24-000016","form_type":"8-K","ticker":"CLPT","cik":"0001285550","company_name":"ClearPoint Neuro, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.682770+00:00","generated_at":"2026-06-07T02:02:28.318310+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"medium","headline":"ClearPoint Neuro reports Q4 2023 preliminary revenue $6.8M (+32% YoY); guides FY2024 revenue $28-32M","bullets":["Preliminary Q4 revenue $6.8M, up 32% YoY; biologics/drug delivery revenue $4.1M (+76% YoY).","Full year 2023 record revenue ~$24M (+17% YoY); biologics/drug delivery $13.6M (+49% YoY).","Cash burn ~$1.2M in Q4; cash and equivalents $23.1M at Dec 31, 2023.","FY2024 revenue guidance $28-32M (17-33% growth); expects multiple product launches including SmartFrame OR and PRISM laser.","Company plans to expand to 100 ClearPoint sites by 2025 and demonstrate operating leverage."],"urls":{"canonical":"https://secwatch.observer/filing/0001285550-24-000016","json":"https://secwatch.observer/filing/0001285550-24-000016.json","markdown":"https://secwatch.observer/filing/0001285550-24-000016.md","text":"https://secwatch.observer/filing/0001285550-24-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285550/000128555024000016/0001285550-24-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285550/000128555024000016/clpt-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:02:28.318310+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5aa27b8e93aa74546b0195868312658590a4eef4","claim":"ClearPoint Neuro, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue approximately $6.8 million.","evidence_excerpt":"a Form 10-K filing for the year with full financial statements. Fourth Quarter 2023 Preliminary Unaudited Financial Highlights • Preliminary unaudited revenue of approximately $6.8 million, a 32% year-over-year increase; • Increased biologics and drug delivery revenue to approximately $4.1 million, a 76% year-over-year increase; and • Cash burn of approximately","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1285550/000128555024000016/0001285550-24-000016-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"approximately $6.8 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}